VGB decreased activation of the mTOR pathway in vivo. by Bo Zhang (6559)

Telomerase inhibition decreases the proliferation and tube formation of HUVECs. by Nadine Mahfouz (4097566)

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

Silencing of dynamin II decreases apoE secretion. by Maaike Kockx (154125)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

VCP inhibition induces accumulation of ubiquitinated-proteins and decreases NFκB-expression. by Kyla Walworth (3150936)

“…The increase in ubiquitinated-protein accumulation in soluble protein-fraction suggests that the DDN^DBeQ treatment alters VCP-function resulting in proteostasis-inhibition and ER-accumulation of these proteins. We also see a significant decrease in expression of tumor-mediator, NFκB in DDN/DDN^DBeQ treated samples as compared to the control-vehicle, although DDN^DBeQ was most effective as anticipated. …”

Proliferative tissue degeneration is accompanied by a sustained decrease in proliferation, acute apoptotic responses, and progressive accumulation of DDR foci. by Catarina M. Henriques (102294)

“…Proliferative tissues such as A) testes, B) head kidney and C) gut sections show sustained significant decrease in proliferation in <i>tert^−/−</i> as compared to <i>tert^+/+</i> siblings (panels b, d and e) (p<0.001) and an acute apoptotic response at 3 months of age (p<0.001), which clears by c. 12 months (panels g, i and j). …”

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

Primers used for analysis of four SNPs in one gene. by Winnie Okore (14139712)

Subjects:

Number of samples per site during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)

Subjects:

<i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

Subjects:

Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

Subjects:

Lower insular perfusion in patients with hypoactive delirium compared with the non-DAT group. by Masashi Takeuchi (1930312)

Nucleotide sequence changes in E6, L1 (MY), and LCR regions from A1/2, D2 and D3 HPV16 variants. by Ana Alfaro (280118)

SrpR binds the centromere-like region <i>srpC</i>. by Nicolas Carraro (650366)

The S75A mutation of LeishIF4E3 leads to a decrease in granule formation in response to PBS starvation and to a reduced interaction with LeishIF4G-4. by Rohit Shrivastava (6459608)

Dose-dependent decreases in cell viability with carboplatin, mitoxantrone, vinblastine, and CBD treatment of canine UC cells. by Jordon M. Inkol (11237604)